Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Arq. bras. cardiol ; 107(5): 403-410, Nov. 2016. tab
Article Dans Anglais | LILACS | ID: biblio-827869

Résumé

Abstract Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI). Glycoprotein IIb/IIIa inhibitors are used in the treatment of no-reflow (NR), but their role to prevent it is unproven. Objective: To evaluate the effect of in-lab administration of tirofiban on the incidence of NR in ST-elevation myocardial infarction (STEMI) treated with PPCI. Methods: STEMI patients treated with PPCI were randomized (24 tirofiban and 34 placebo) in this double-blinded study to assess the impact of intravenous tirofiban on the incidence of NR after PPCI according to angiographic and electrocardiographic methods. End-points of the study were: TIMI-epicardial flow grade; myocardial blush grade (MBG); resolution of ST-elevation < 70% (RST < 70%) at 90min and 24h after PPCI. Results: Baseline anthropometric, clinical and angiographic characteristics were balanced between the groups. The occurrence of TIMI flow < 3 was not significantly different between the tirofiban (25%) and placebo (35.3%) groups. MBG ≤ 2 did not occur in the tirofiban group, and was seen in 11.7% of patients in the placebo group (p=0.13). RST < 70% occurred in 41.6% x 55.8% (p=0.42) at 90min and in 29% x 55.9% (p=0.06) at 24h in tirofiban and placebo groups, respectively. Severe NR (RST ≤ 30%) was detected in 0% x 26.5% (p=0.01) at 90 min, and in 4.2% x 23.5% (p=0.06) at 24h in tirofiban and placebo groups, respectively. Conclusion: This pilot study showed a trend toward reduction of NR associated with in-lab upfront use of tirofiban in STEMI patients treated with PPCI and paves the way for a full-scale study testing this hypothesis.


Resumo Fundamento: Mesmo com abertura da artéria coronária culpada bem sucedida, a reperfusão miocárdica nem sempre sucede a intervenção coronariana percutânea primária (ICPP). Inibidores da glicoproteína IIb/IIIa são usados no tratamento do fenômeno de não reperfusão (NR), mas seu papel para preveni-lo não está comprovado. Objetivo: Avaliar o efeito da administração, em laboratório, de tirofibana sobre a incidência de NR em infarto agudo do miocárdio com supra do segmento ST (IAMCSST) tratado com ICPP. Métodos: Pacientes com IAMCSST tratados com ICPP foram randomizados (24 tirofibana e 34 placebo) neste estudo duplo-cego para avaliar o impacto de tirofibana intravenosa sobre a incidência de NR após ICPP de acordo com métodos angiográficos e eletrocardiográfico. Os desfechos do estudo foram: fluxo epicárdico TIMI (grau), grau de fluxo miocárdico (MBG), resolução da elevação do segmento ST < 70% (RST < 70%) aos 90 minutos e 24 horas após ICPP. Resultados: Características antropométricas, clínicas e angiográficas basais eram equilibradas entre os grupos. A ocorrência de fluxo TIMI < 3 não foi significativamente diferente entre os grupos tirofibana (25%) e placebo (35,3%). MBG ≤ 2 não ocorreu no grupo tirofibana, e foi detectado em 11,7% dos pacientes do grupo placebo (p=0,13). RST < 70% ocorreu em 41,6% x 55,8% (p=0.42) aos 90 minutos, e em 29% x 55,9% (p=0,06) em 24 horas nos grupos tirofibana e placebo, respectivamente. NR grave (RST ≤ 30%) ocorreu em 0% x 26,5% (p=0,01) aos 90 minutos, e em 4,2% x 23,5% (p=0,06) em 24 horas nos grupos tirofibana e placebo, respectivamente. Conclusão: Este estudo piloto mostrou uma tendência de redução de NR associada ao uso, em laboratório, de tirofibana em pacientes com IAMCSST tratados com ICPP, e abre caminho para um estudo em escala real que teste essa hipótese.


Sujets)
Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Complications postopératoires/prévention et contrôle , Tyrosine/analogues et dérivés , Antiagrégants plaquettaires/usage thérapeutique , Phénomène de non reperfusion/prévention et contrôle , Intervention coronarienne percutanée , Infarctus du myocarde/chirurgie , Placebo , Complications postopératoires/diagnostic , Complications postopératoires/épidémiologie , Facteurs temps , Tyrosine/administration et posologie , Tyrosine/usage thérapeutique , Perfusions veineuses , Brésil/épidémiologie , Antiagrégants plaquettaires/administration et posologie , Endoprothèses , Projets pilotes , Valeur prédictive des tests , Phénomène de non reperfusion/diagnostic , Phénomène de non reperfusion/épidémiologie , Tirofiban
2.
Journal of Zanjan University of Medical Sciences and Health Services. 2010; 18 (71): 90-97
Dans Persan | IMEMR | ID: emr-105512

Résumé

Nowadays primary PCI [Percutaneous Coronary Intervention] is the treatment of choice for ST Elevation Myocardial Infarction and has absolute advantage to classic thrombolytic drug therapy. But primary PCI itself has an important drawback that is "no reflow phenomenon". In recent years several medical and mechanical solutions have introduced to overcome this problem. Gradually manual thrombus suction established as an effective mechanical and safe method. In this report we present the first patient who treated by primary PCI and manual thrombus suction in Zanjan province with completely successful results


Sujets)
Humains , Angioplastie coronaire par ballonnet , Phénomène de non reperfusion/prévention et contrôle , Thrombose/thérapie , Aspiration (technique) , Reperfusion myocardique , Résultat thérapeutique
SÉLECTION CITATIONS
Détails de la recherche